UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Durability of rilpivirine- versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Article
  • Authors:
    Gagliardini R, Gianotti N, Maggiolo F, Cozzi-Lepri A, Antinori A, Nozza S, Lapadula G, De Luca A, Mussini C, Gori A, Saracino A, Andreoni M, Monforte AD, ICONA Foundation Study Group
  • Publication date:
    19/07/2021
  • Pagination:
    106406
  • Journal:
    International Journal of Antimicrobial Agents
  • Status:
    Published
  • Country:
    Netherlands
  • PII:
    S0924-8579(21)00171-0
  • Language:
    eng
  • Keywords:
    antiretroviral naïve, dolutegravir, elvitegravir, raltegravir, rilpivirine, single tablet regimen
Abstract
OBJECTIVE: Comparisons between rilpivirine (RPV) and integrase strand transfer inhibitors (INSTIs) in antiretroviral therapy (ART)-naïve HIV-infected individuals are currently lacking. Aim of the study was to compare, in an observational cohort setting, the durability of treatment of RPV- and INSTI-based first-line regimens. METHODS: Patients who started first-line ARTs based on RPV or on INSTIs, with HIV-RNA <100,000 copies/mL, CD4 cells count >200 cells/μL, were included. The primary endpoint was the cumulative probability of treatment failure (TF = virological failure [confirmed HIV-RNA >50 copies/mL] or discontinuation of the anchor drug in the regimen), as assessed by Kaplan-Meier method. A multivariable Cox regression was used to control for potential confounding. RESULTS: Of 1991 patients included, 986 started ART with a RPV- and 1,005 with an INSTI-based regimen. The median (IQR) follow-up was 20 (10, 35) months. The cumulative two-years probability of TF with RPV (9.1% [95% 7.2, 11.1]) was lower than that observed in the INSTI group (16.6% [13.8, 19.4], p=0.0002) but not when comparing with dolutegravir (DTG) alone. Starting ART with an INSTIs-based regimen vs. RPV was associated with a higher risk of TF after controlling for potential confounding factors (AHR [95%CI]: 1.64 [1.28, 2.10]; p<0.001). Results were similar when restricting the analysis to STR regimens, although the probability of virological success was higher for INSTI and for DTG. CONCLUSIONS: In ART-naïve patients with low viral load and high CD4 count, the risk of treatment failure was lower in patients who started RPV- vs. INSTIs-based regimens other than DTG-based ones.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Infection & Population Health
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by